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Objectives: Since electronic prescribing is limited to few hospitals, point prevalence surveys, such as the stan-
dardized European Surveillance of Antimicrobial Consumption point prevalence survey (ESAC PPS), are an
alternative tool for monitoring prescribing and helping to identify performance indicators and prescribing
trends. The main objective of this study was to identify and assess targets for quality improvement.
Methods: Each hospital had to carry out the survey within 2 weeks. Each department had to be surveyed in
1 day. Data collected, for all inpatients, included age and gender. For patients on systemic antimicrobial treat-
ment, the antimicrobial/s, infection/prophylaxis site, reason in medical notes and guideline compliance were
also collected. A central database using a web-based tool (WebPPS) developed in-house was used for data
entry.
Results: Combination of two or more antimicrobials accounted for 30% of use. Surgical prophylaxis was pro-
longed (.1 day) in 53% of cases. ‘Intensive care’ had higher proportions of treated patients (53% versus
29%), combination therapy (49% versus 31%), hospital-acquired infections (49% versus 31%) and parenteral
administration (91% versus 61%). ‘Reason in notes’ was documented in 76%, and ‘guideline compliance’
occurred in 62% of patients.
Conclusions: The ESAC PPS provided useful information on the quality of prescribing, which identified a number
of targets for quality improvement. These could apply to specific departments or whole hospitals. Intensive
care, which has different characteristics, should not be compared with general wards with respect to combi-
nation therapy, hospital-acquired infections or parenteral proportion. The study confirmed that the ESAC PPS
methodology can be used on a large number of hospitals at regional, national, continental or global level.
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Introduction
Until the turn of the century there were limited reliable data on
antimicrobial utilization in hospitals.1 However, a temporal
relationship between antimicrobial use and resistance had
already been demonstrated.2,3 The use of certain antimicrobials
is also associated with higher levels of resistance, e.g. quinolones
are more prone to generate resistance compared with
b-lactams.4,5 These data highlight the importance of surveillance
of antimicrobial use, even at the patient level. The best way to
monitor prescribing would be through monitoring electronic pre-
scribing in hospitals. However, to date, this is a rare luxury
available only in a limited number of countries/hospitals.6 There-
fore, point prevalence surveys (PPSs) are a practical surveillance
tool for this purpose.7 PPSs can identify targets for quality
improvement for particular clinical departments, as well as
changes in prescribing trends over time. The European Surveil-
lance of Antimicrobial Consumption (ESAC) PPS is a standard-
ized methodology on the quality of antimicrobial use within
hospitals.8
The main objectives of the extensive ESAC 2009 Hospital PPS
were to confirm targets for quality improvement that had
already been identified in the previous two smaller PPSs and
possibly identify others in view of the larger sample of hospitals.
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Such targets for quality improvement should, in turn, be utilized
by the individual participating hospitals, or even at a national
level, in order to improve deficient areas of practice. Furthermore,
the feasibility of carrying out the survey in a larger sample of
hospitals was being evaluated. The number of participating hos-
pitals increased to 172, compared with the 20 hospitals of 2006
and 50 hospitals of 2008, by the time the data were extracted
for analysis.
Methods
Hospitals and countries
The ESAC Hospital Care National Representatives who each recruited two
hospitals to perform the PPS in 2008 were asked to add as many more
hospitals as possible for the 2009 PPS. The 2009 PPS was performed in
172 hospitals from 25 European countries based on a simplified version
of the protocol of the 2006 PPS.8 The 25 countries that took part in the
2009 PPS were Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic,
Denmark, England, Estonia, France, Hungary, Ireland, Israel, Italy, Latvia,
Malta, Northern Ireland, Norway, Portugal, Russian Federation, Scotland,
Slovenia, Spain, Switzerland and Wales. Thus six of the countries that
participated in PPS 2006 did not participate in PPS 2009; however, the
participation of another 11 countries resulted in a net increase of
5 countries participating in PPS 2009.8
The WebPPS software
A new web application, WebPPS, was specifically developed by ESAC for
data entry, automated feedback and reporting for the participating hos-
pitals. This was first piloted during PPS 2008 and was used on the larger
hospital sample in PPS 2009. Data were entered locally into the appli-
cation. Upon finalization and validation of data entry the hospital could
extract a report for all hospitals with validated data. If more than two
hospitals validated their data from a specific country, there was also
the option to create a report for the specific country. Either of the above-
mentioned reports can be rerun even now for all hospitals that had vali-
dated their data.
WebPPS is a web application developed in Java where data are backed
up in a Postgresql database for which free software has been used.
Essentially, the program mapped the paper forms to web forms. In
addition, a personal digital assistant (PDA) form was also developed in
order to use these devices for data entry.
Hospital categorization
The hospitals had to fill in a questionnaire and classify themselves as
primary, secondary, tertiary care or specialized hospitals. Whilst there is
natural overlap in the different types of healthcare there are distinctions
between primary (e.g. general practice and basic district hospital ser-
vices), secondary (district hospitals with basic specialty functions such
as obstetrics) and tertiary healthcare (specialized care, usually on referral
from primary or secondary medical care personnel, with facilities for
special investigations and treatment). In addition they had to declare
whether they were teaching hospitals. Teaching hospitals could be both
those linked to universities providing only undergraduate training, those
providing specialization training or both.
Data collection
Data on antibiotic use were collected by dedicated team/s, comprising
infectious diseases specialists, microbiologists, pharmacists and infection
control nurses, for all inpatients within a maximum of two consecutive
weeks. Most of the hospitals carried out the survey between May and
June 2009. However, the Belgian hospitals carried out the survey in
November 2009. Furthermore, reminders were sent to those hospitals
who had carried out the survey, entered but did not validate their data.
In order to be included in the survey, patients had to be admitted in the
hospital for at least 24 h before the survey and still present at 0800 on
the day of survey. For surgical patients, administration of prophylactic
antimicrobials was checked for the previous day to code the duration
of prophylaxis as either one dose, 1 day or .1 day. The number of
patients in each ward was used as denominator. Depending on the
number of beds, hospitals decided to complete the survey on either
one or more days. However, all beds in each department had to be com-
pleted in a single day. For each patient treated with systemic antimicro-
bials, information was collected on age, gender, antimicrobial agent/s
(dose per administration, number of doses per day and route of admin-
istration), anatomical site of infection or target for prophylaxis according
to the list of diagnosis groups, indication for therapy and whether the
indication was actually documented in medical records. Whenever the
reasons for treatment were not documented, the ward doctors in
charge of the patient’s care were contacted in order to obtain such infor-
mation. Compliance with local guidelines was also requested but not
assessed centrally.
Antimicrobial use was reported as the number of treated patients and
the number of therapies. Therapy was defined as the use of one sub-
stance by one route of administration. Data were entered on the
central database (based at the University of Antwerp, Belgium) using
the web-based tool developed internally, WebPPS. This was done
locally, within the hospital, after completing paper forms in the wards.
Statistical analysis
A simulation method was used to select 30 samples of 74 hospitals with
not more than 5 hospitals per country in order to determine whether the
results would change. If the results were significantly different, this would
have implied an over-representation of countries with high participation.
The Kruskal–Wallis one-way analysis of variance by rank, a non-
parametric method for testing equality of population medians between
groups, was used to determine whether there was any significant differ-
ence in population and or indicators (P value for all was consistently close
to 1, i.e. non-significant). The outcome showed no significant difference
between any of the samples and the total data set, therefore it was
decided to carry out the analysis using all 172 hospitals. The z-test
was used to determine whether differences in proportions between
sets of data for different departments were large enough to be statisti-
cally significant.
Results
Hospital overview
Twenty-five countries participated in the ESAC PPS 2009 with 172
hospitals including 21 primary, 89 secondary, 57 tertiary and 5
specialized hospitals. The median number of hospitals per
country was 3 (range 1–45). Since hospital participation was
exclusively on a voluntary basis the number of hospitals was
not intended to be representative. Teaching hospitals amounted
to 76 (44.2%).
Patient demographics and overview of prescribing
A total of 73060 patients were enrolled, of whom 21194 (29.0%)
were prescribed 29665 antimicrobial therapies. Intensive care
Zarb et al.
444
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/66/2/443/718696 by U
niversity of M
alta user on 26 June 2019
departments had the highest proportion of treated patients,
often receiving more than one agent.
The majority of patients received monotherapy [median of
68.9% of patients; interquartile range (IQR) 61.5%–77.1%].
Data for proportion of treated patients, parenteral route of
administration, inclusion of reason in patient notes, compliance
with local guidelines and combination therapy for the different
department categories, are summarized in Table 1.
Route of administration
A mean of 60.5% of antimicrobials were administered via the
parenteral route. The proportion of parenteral use differed con-
siderably in the participating hospitals and specialties
(Figure 1). The parenteral proportion was significantly higher
(P,0.0001) in intensive care with respect to the three other cat-
egories. The reason for starting antibiotics was a key factor in the
selection of the route of administration. Medical prophylaxis had
the only relevant proportion (3.3%) of inhaled treatment, mainly
for the respiratory site (e.g. for cystic fibrosis) with the oral route
being predominant (64.4%). In surgical prophylaxis, parenteral
administration was used in 82% of cases. Community-acquired
infection (CAI) and hospital-acquired infection (HAI) had similar
proportions of oral therapy, 42.5% and 36.6%, respectively,
with the rest almost exclusively parenteral. Fluoroquinolones
(J01MA) (68.6% oral) and penicillins (J01C) (35.9% oral) are
available for both oral and parenteral use. The most used
fluoroquinolone, ciprofloxacin, had only 29.7% parenteral use,
whilst co-amoxiclav, the most used penicillin, had 52.6%
parenteral use.
Reason in notes
The reason for which antimicrobials were prescribed was
recorded in three-quarters of the patients’ medical records.
This varied in the different hospitals with a median of 80.0%
(IQR, 69.9%–87.7%). Analysing the same data by specialty
yielded a significantly higher inclusion of reason in notes for
‘Intensive care’ and ‘Medical’ departments with respect to
‘Other’ and ‘Surgical’ departments (P,0.0001). Neither the
difference between ‘Intensive care’ and ‘Medical’ departments,
nor the difference between ‘Other’ and ‘Surgical’ departments
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Figure 1. Box and whisker plot showing the proportion (and range) of parenteral antimicrobials within participating hospitals and the respective
specialties.
Table 1. Overview of patients and indicators by department
Parameter description
Department
All hospitalintensive care medical other surgical
Number of hospitals 153 169 57 162 172
Number of included patients (range) 3894 (2–310) 43577 (14–1781) 2323 (3–251) 23242 (17–2771) 73060 (2–680)
Number of treated patients (%) 2068 (53.1) 11690 (26.8) 251 (10.8) 7188 (30.9) 21197 (29.0)
Number of prescriptions 3425 16155 345 9740 29665
Parenteral therapy, % (range) 90.8 (0–100) 50.3 (0–100) 46.1 (0–100) 67.3 (0–77.8) 60.5 (0–67.6)
Reason in notes, %a 79.0 78.9 69.9 69.4 75.7
Guidelines compliant, %a 66.8 64.3 54.2 56.1 62.0
Combination therapy, % (range) 48.6 (0–100) 30.2 (0–100) 29.9 (0–100) 30.4 (11.1–100) 32.1 (0–94.4)
Note values and percentages refer to actual overall values for the complete data set.
aRange for reason in notes and guideline compliance was 0–100% for all specialties.
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was significant. The reason was more frequently included in
patients’ notes when the indication was infection (80.8%) as
opposed to prophylaxis (54.2%). There was no significant differ-
ence between the type of infection (CAI 81.8%; HAI 79.2%) or
type of prophylaxis (surgical 55.0%; medical 53.3%).
Compliance with local guidelines
The overall compliance with local guidelines was 62.8%. The
difference between departments, once again, showed that ‘Inten-
sive care’ had, significantly, the best compliance rate followed by
‘Medical’ (P¼0.0061), ‘Surgical’ (P,0.0001) and ‘Other’
(P,0.0001) departments, respectively.
Antimicrobial use by Anatomical Therapeutic Chemical
(ATC) classification
Stratifying at the second level of the WHO ATC classification (ATC-2),
89.7% of the prescribed antibiotics were antibacterials—J01.
Systemic antifungals—J02—was the second class in ‘Intensive
care’ (5.6%) whilst minimally used in ‘Surgical’ departments
(1.2%). The ‘other antimicrobials’, mainly oral/rectal metronidazole
were second in both ‘Medical’ and ‘Other’ departments (5.2%,
7.9%).
At ATC level 3 (ATC-3) penicillins were the most used class
(J01C: 35.0%), followed by the other b-lactams (J01D: 17.1%)
and ‘other antibacterials’ (J01X: 12.6%). The most utilized
class, at ATC level 4 (ATC-4), was the penicillins/b-lactamase
inhibitors (J01CR: 22.1%) followed by the fluoroquinolones
(J01MA: 9.1%). At ATC level 5 (ATC-5), amoxicillin/b-lactamase
inhibitor was the most used substance [J01CR02: 15.0% (7.9%
parenteral; 7.1% oral)]. Differences between the different spe-
cialties especially between ‘Intensive care’ departments and
the other categories were observed. ‘Intensive care’ had a
higher use of piperacillin/b-lactamase inhibitor (J01CR05) whilst
all other specialties mainly used amoxicillin/b-lactamase
inhibitor (J01CR02).
Antimicrobial use by indication
The penicillin/b-lactamase inhibitor ATC-4 category was preva-
lent in most indications. Amoxicillin/b-lactamase inhibitor
(J01CR02) was the most common antimicrobial for surgical pro-
phylaxis (20.0%) and CAI (17.8%) while piperacillin/b-lactamase
inhibitor (J01CR05) was most common in HAI (11.5%). For
medical prophylaxis different antimicrobials were used. Sul-
phonamides, namely co-trimoxazole—J01EE01 (14.5%)—was
the most utilized antimicrobial followed by the triazole
derivatives—J02AC, mainly fluconazole—J02AC01 (18.6%).
Antimicrobial use by diagnostic site of infection
The top four indication sites accounted for .75% of cases. The
respiratory tract was the most common site (27.2%), followed
by skin, soft-tissue, bone, joint (SSTBJ) (19.0%), gastrointestinal
tract (GIT) (17.2%) and urinary tract (12.9%). The four most uti-
lized antimicrobials were co-amoxiclav (20.0% of respiratory),
flucloxacillin (19.9 of SSTBJ), parenteral metronidazole (18.0%
of GIT) and trimethoprim (18.8% of urinary tract infections).
The most utilized antimicrobial was different for the different
indications. However, co-amoxiclav ranked second in the other
three sites indicating that its use is not limited to specific sites.
Antimicrobial use for surgical prophylaxis
The top five antibiotics for surgical prophylaxis were amoxicillin/
b-lactamase inhibitor (20.0%), cefuroxime (17.1%), cefazolin
(12.4%) metronidazole (10.4%) and gentamicin (6.9%).
However, metronidazole was hardly ever used as a single agent
(only 16 patients), but mainly combined with cefuroxime 129
times (32.6%). Amoxicillin/b-lactamase inhibitor was the most
used for all sites whilst cefuroxime and cefazolin were mostly
used in SSTBJ, metronidazole in GIT and gentamicin for urinary
tract operations.
Prophylaxis was generally prolonged, in the majority of cases
for .1 day, for all operation sites (Figure 2). For the most used
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Figure 2. Duration of surgical prophylaxis by operation site. The number of cases for each of the categories is shown in brackets. Categories: SSTBJ,
skin, soft tissue, bone and joint; GI, gastrointestinal; UT, urinary tract; CVS, cardiovascular system; GUOB, gynaecology and obstetrics; ENT,
otorhinolaryngology; RESP, respiratory; EYE, ophthalmic.
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antimicrobial, co-amoxiclav, .1 day duration was used in 59.3%
of cases. Ceftriaxone, which has a long half-life, was used for
.1 day in 73.0% of cases. Alternatives to prolonged prophylaxis
included gentamicin, used as a single dose 74.6% of the time,
and flucloxacillin, used for 1 day in 51.5% of cases.
HAI
HAI accounted for 30.7% of all antimicrobial therapies. The pro-
portion was highest in ‘Intensive care’ (48.9%), 30% in ‘Surgery’
and 27% in both ‘Medical’ and ‘Other’ departments. Hospital-
specific antimicrobials such as glycopeptides and carbapenems
were more utilized in ‘Intensive care’. Respiratory infections
(26.8%) were the most common HAI in ‘Intensive care’
(38.5%) and ‘Medical’ (29.7%) departments, urinary tract infec-
tions (23.4%) were the most common in ‘Other’ departments
whilst SSTBJ HAIs (32.7%) were the most common in ‘Surgical’
departments.
Combination therapy
Combination therapy was used in 6794 (32.1%) patients. Table 2
highlights the most frequently used combinations and the
respective aetiologies and sites. Figure 3 highlights the fact
that monotherapy prevailed across the different departments
and indications. However, ‘Intensive care’ showed a significantly
higher proportion of combination therapy (P,0.0001). The
difference between the other departments was not significant.
Discussion
The ESAC PPS is a proven success because the number of partici-
pating hospitals, from the 20 of the pilot PPS (2006), increased to
50 (2008) and reached 172 hospitals in 2009. It took the surveil-
lance programme in the USA a quarter of a century to increase
from 19 to 230 hospitals.9 This fact proves that our objective
of evaluating the feasibility of carrying out the survey in a
larger sample of hospitals was achieved successfully. The great
variation in antibiotic stewardship initiatives across Europe high-
lights an urgent need for standardization and agreement on the
principles and key components.10 Southern Europe is a region
requiring more work on this matter.11
Various indicators have been established with respect to anti-
biotic prescribing. Amelioration in these indicators is desired in
order to improve patient outcomes. When PPSs are carried out
Table 2. Top antimicrobial combinations and respective indications for which they were used
Combination Aetiology Main site Main diagnosis Number Combination, %
Co-amoxiclav+clarithromycin CAI Resp CAP 289 91
Benzylpenicillin+flucloxacillin CAI SSTBJ SST 163 94
Cefuroxime+metronidazole CAI GI IA 89 42
Surg proph GI ProphGI 55 26
Amoxicillin+clarithromycin CAI Resp CAP 105 75
Co-amoxiclav+metronidazole CAI GI IA 29 35
Surg proph GI ProphGI 18 22
Ceftriaxone+metronidazole CAI GI IA 29 47
Surg proph GI ProphGI 18 29
Piperacillin/tazobactam+metronidazole Surg proph GI ProphGI 31 56
Abbreviations: CAI, community-acquired infection; Surg proph, surgical prophylaxis; CAP, community-acquired pneumonia; IA, intra-abdominal;
ProphGI, prophylactic gastrointestinal; SST, skin and soft tissue; Resp, respiratory; GI, gastrointestinal; SSTBJ, skin and soft tissue or bone and joint.
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repeatedly these can help verify any changes in targeted area/s
of practice, previously identified as performance indicators. One
of these indicators is the switch from intravenous to oral
therapy when the patient improves. Patients with an appropriate
early switch to oral therapy have a shorter length of hospital
stay, and require less nursing time.12,13 This form of benchmark-
ing is more appropriate for comparison of repeated PPSs within
the same hospital since the case mix would tend to be more
or less stable. On the other hand different hospitals might
have a very different case mix and therefore a different need
for parenteral therapy.
Another indicator that can be monitored by PPS is guideline
compliance, an indicator that is applicable to any area of practice
and not exclusively to antibiotics.14 – 16 In our study the compli-
ance was relatively low at 62% with slightly better results for
‘Intensive care’. However, ESAC could not assess the answers
given by the hospitals. The answers to this parameter could be
biased by the surveyors’ perspective.
The inclusion of the reason why therapy was started in the
patient’s medical notes (Reason in notes) is an indicator not pre-
viously well documented in the literature. ESAC PPS has identified
this parameter as a key performance indicator. It allows intellig-
ibility and statement of practice, as well as facilitating measure-
ment of prescribing quality. Whatever the baseline compliance
(median 80%, IQR 70%–88%, in this study) there is room for
improvement especially for the less compliant outliers. Once
again, ‘Intensive care’ was the better performing department,
along with the ‘Medical’ department. The facts that patients
are sicker and the nurse-to-patient (and doctor-to-patient)
ratios are higher in ‘Intensive care’ may possibly contribute to
higher documentation of the indication/reason why a patient is
prescribed any pharmacological agents including antimicrobials.
The lower documentation rate observed in surgical departments
could mainly be due to the fact that, most of the time, the
indication is excessively prolonged surgical antimicrobial
prophylaxis.
HAIs represent a serious public health problem.17 The
prevalence of HAI is also another performance indicator that
is often overlooked.18 Surveillance of HAI, which has been
identified as a clinical performance indicator, has been
ongoing in the USA since 1970.9 ‘Intensive care’, as expected,
had the highest prevalence of HAI with almost half of the
treated patients being treated for an HAI, not necessarily
acquired within the ‘Intensive care’ setting. In fact, 8.0% of
HAIs were imported from another hospital and not just a
different department within the same hospital. Therefore,
one has to factor this in, in order to minimize potential bias,
since in such cases the HAI cannot be attributed to the
surveyed hospital. This is more relevant when the PPS aims
to benchmark the hospitals.
Most antimicrobial combinations are clinically justified, e.g.
the use of a b-lactam plus a macrolide for community-acquired
pneumonia.19,20 However, the combination of metronidazole
with either co-amoxiclav, piperacillin/tazobactam or carbape-
nems indicates an anti-anaerobe overkill, which is not clinically
warranted.21 In this study, such combinations accounted for
8.5% of combination and 2.7% of all therapies.
Empirical treatment requires a wide spectrum of cover;
however, in a PPS there is always a mixture of newly prescribed
therapies and cases where the culture and susceptibility results
are available and therefore therapy should have been changed
accordingly. The antimicrobial selection for particular indications
was therefore, identified as another target for quality improve-
ment. In general, a higher proportion of narrow-spectrum
agents suggests a better performance than a higher proportion
of broad-spectrum second-line antimicrobials.22 In the case of
hospital-specific antimicrobials this is much less of a bias issue.
An elevated use of hospital-specific antimicrobials either in the
general wards or for CAI is another quality indicator that
should be targeted. The tendency is that countries with high
antibiotic use also have high use of hospital-specific antimicro-
bials.23 A study in Latvia recorded an increase in the use of anti-
microbial agents including an increase in the proportion of
hospital-specific antimicrobials.24 It is probable that this trend
would be observed elsewhere unless specific antibiotic steward-
ship measures are implemented.
Another area of concern was the excessively prolonged dur-
ation of surgical antibiotic prophylaxis for .1 day. Surgical pro-
phylaxis should cover the peri-operative period only and a
single dose is usually enough unless there is extensive blood
loss or the procedure is prolonged.25
Individual hospitals could decide to prioritize and focus on
specific departments in order to improve selected quality indi-
cators. However, better-performing departments should not be
neglected in order to ensure they maintain the level of practice
and also as a benchmark for other departments. Any bench-
marking has to be done either by observing trends within the
same hospital/units or by comparing similar types of hospital,
especially for oral-to-parenteral ratio, since tertiary referral
centres would be expected to have a higher use of parenteral
therapy compared with primary hospitals. The fact that there is
no international standardized hospital categorization system is
a major limitation in comparing hospitals, especially from differ-
ent countries, ensuring they have a similar case mix. However,
for duration of surgical prophylaxis, compliance with guidelines
or documentation of the reason for starting therapy in notes
should not be affected by the type of hospital.
This study confirms the findings of the first ESAC PPS that a
web-based method for PPS offers a standardized instrument
that can identify targets for quality improvement.8 Furthermore,
this study identified performance indicators not identified in the
previous ESAC PPSs. These include the proportions of HAIs, guide-
line compliance and combination therapy. The WebPPS is also a
dynamic tool that, besides providing a standardized method-
ology, is also adaptable to different research and/or surveillance
questions enabling the PPS organizers to modify the software to
fit their needs. The WebPPS developed by ESAC has now been
modified to include HAI surveillance, in addition to antimicrobial
use, for the European Centre for Disease Prevention and Control
(ECDC) PPS. The antimicrobial part is based on the ESAC PPS
whilst the HAI part is based mainly on Improving Patient
Safety in Europe/Hospital in Europe Link for Infection Control
through Surveillance (IPSE/HELICS) and CDC/National Healthcare
Safety Network (CDC/NHSN) case definitions.26
In conclusion, ESAC developed a web-based application
(WebPPS), which was used successfully across Europe. Areas of
practice where improvement is required can be identified using
the WebPPS PPS tool. Hospitals can audit and feed back the
results instigating improvement in practice. The ESAC WebPPS
software is also available for other countries outside Europe.
Zarb et al.
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Some European hospitals now have access to an amended
WebPPS tool for a combined PPS on HAI and antimicrobial use.
This new PPS protocol and WebPPS tool is currently being
piloted and will be rolled out for a representative European PPS
on HAI and antimicrobial use in 2011.
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